FI70925C - Foerfarande foer framstaellning av 3-hydroxy-ml-236b-derivaterm-4 och m4' - Google Patents

Foerfarande foer framstaellning av 3-hydroxy-ml-236b-derivaterm-4 och m4' Download PDF

Info

Publication number
FI70925C
FI70925C FI823978A FI823978A FI70925C FI 70925 C FI70925 C FI 70925C FI 823978 A FI823978 A FI 823978A FI 823978 A FI823978 A FI 823978A FI 70925 C FI70925 C FI 70925C
Authority
FI
Finland
Prior art keywords
nocardla
ferm
compound
brown
microorganism
Prior art date
Application number
FI823978A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI823978L (fi
FI823978A0 (fi
FI70925B (fi
Inventor
Akira Terahara
Minoru Tanaka
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of FI823978A0 publication Critical patent/FI823978A0/fi
Publication of FI823978L publication Critical patent/FI823978L/fi
Publication of FI70925B publication Critical patent/FI70925B/fi
Application granted granted Critical
Publication of FI70925C publication Critical patent/FI70925C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/365—Nocardia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/872—Nocardia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI823978A 1981-11-20 1982-11-19 Foerfarande foer framstaellning av 3-hydroxy-ml-236b-derivaterm-4 och m4' FI70925C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18664181 1981-11-20
JP56186641A JPS5889191A (ja) 1981-11-20 1981-11-20 ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法

Publications (4)

Publication Number Publication Date
FI823978A0 FI823978A0 (fi) 1982-11-19
FI823978L FI823978L (fi) 1983-05-21
FI70925B FI70925B (fi) 1986-07-18
FI70925C true FI70925C (fi) 1986-10-27

Family

ID=16192138

Family Applications (1)

Application Number Title Priority Date Filing Date
FI823978A FI70925C (fi) 1981-11-20 1982-11-19 Foerfarande foer framstaellning av 3-hydroxy-ml-236b-derivaterm-4 och m4'

Country Status (18)

Country Link
US (1) US4537859A (ref)
JP (1) JPS5889191A (ref)
KR (1) KR880002483B1 (ref)
AT (1) AT387585B (ref)
AU (1) AU551720B2 (ref)
BE (1) BE895080A (ref)
CA (1) CA1186647A (ref)
CH (1) CH651065A5 (ref)
DE (1) DE3242849A1 (ref)
DK (1) DK159328C (ref)
ES (1) ES517542A0 (ref)
FI (1) FI70925C (ref)
FR (1) FR2516935A1 (ref)
GB (1) GB2111052B (ref)
IT (1) IT1191235B (ref)
NL (1) NL194373C (ref)
SE (1) SE453996B (ref)
ZA (1) ZA828535B (ref)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3682557D1 (de) * 1985-09-13 1992-01-02 Sankyo Co Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5116870A (en) * 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
USRE36481E (en) * 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
EP0306263B1 (en) * 1987-09-02 1992-03-18 Merck & Co. Inc. Novel hmg-coa reductase inhibitors
US4997848A (en) 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
EP0337548A3 (en) * 1988-04-15 1991-08-14 Merck & Co. Inc. HMG-COA reductase inhibitors produced by nocardia SP. (MA6455)(ATCC 53695)
US4997755A (en) * 1988-04-15 1991-03-05 Merck & Co., Inc. HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
US4963538A (en) * 1988-06-29 1990-10-16 Merck & Co., Inc. 5-oxygenated HMG-CoA reductase inhibitors
US4937259A (en) * 1989-06-09 1990-06-26 Merck & Co., Inc. Antihypercholesterolemic compounds
US4970231A (en) * 1989-06-09 1990-11-13 Merck & Co., Inc. 4-substituted HMG-CoA reductase inhibitors
US5041562A (en) * 1989-06-09 1991-08-20 Merck & Co., Inc. 3-keto HMG-CoA reductase inhibitors
US5001241A (en) * 1989-06-09 1991-03-19 Merck & Co., Inc. 3-KETO HMG-CoA reductase inhibitors
US5010105A (en) * 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US4997849A (en) * 1989-06-23 1991-03-05 Merck & Co., Inc. Microbial transformation of simvastatin
US5112857A (en) * 1990-09-04 1992-05-12 Merck & Co., Inc. Hmg-coa reductase inhibitor metabolites
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
IL108432A (en) * 1993-01-29 1997-09-30 Sankyo Co DERIVATIVES OF 3, 5-DIHYDROXY-7- £1, 2, 6, 7, 8, 8a-HEXAHYDRO-2- METHYL-8- (SUBSTITUTED ALKANOYLOXY)-1-NAPHTHYL| HEPTANOIC ACID AND THEIR LACTONES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6043064A (en) * 1993-10-22 2000-03-28 Bristol-Myers Squibb Company Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
US5942423A (en) 1995-06-07 1999-08-24 Massachusetts Institute Of Technology Conversion of compactin to pravastatin by actinomadura
SI9800144A (sl) 1998-05-21 1999-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Nov biotehnološki postopek pridobivanja 3-hidroksi-ML-236B derivatov poznanih kot M-4 in M-4'
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
CA2358927A1 (en) * 1999-01-20 2000-07-27 Shin-Ichi Hashimoto Process for producing hmg-coa reductase inhibitors
CA2360080A1 (en) 1999-01-29 2000-08-03 Kyowa Hakko Kogyo Co. Ltd. Process for producing hmg-coa reductase inhibitor
US6682913B1 (en) 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
CN1468098A (zh) * 2000-10-05 2004-01-14 �ݰ¸Ƕ�ҩ�����޹�˾ 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
JP2003093045A (ja) * 2001-09-26 2003-04-02 Godo Shusei Co Ltd 有用変換微生物
US20050113577A1 (en) * 2002-04-16 2005-05-26 Karki Shyam B. Solid forms of slats with tyrosine kinase activity
RU2217141C1 (ru) * 2002-11-20 2003-11-27 Балавадзе Михаил Элизбарович Состав "витализин-1" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
KR100470078B1 (ko) * 2003-06-12 2005-02-04 씨제이 주식회사 컴팩틴을 프라바스타틴으로 전환할 수 있는 스트렙토마이세스 종(Ｓｔｒｅｐｔｏｍｙｃｅｓ ｓｐ.)ＣＪＰＶ 975652 및 그를 이용한 프라바스타틴의 제조방법
CA2535359A1 (en) 2003-08-21 2005-03-03 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
US20050101927A1 (en) * 2003-09-11 2005-05-12 Kimberly-Clark Worldwide, Inc. Absorbent products comprising a moisturizing and lubricating composition
AU2004293013B2 (en) 2003-11-19 2011-04-28 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
TWI252253B (en) * 2004-01-09 2006-04-01 Chinese Petroleum Corp A novel Pseudonocardia sp RMRC PAH4 and a process for bioconverting compactin into pravastatin using the same
KR100637762B1 (ko) * 2004-07-30 2006-10-23 주식회사 지니스 저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
US20110217412A1 (en) * 2004-07-30 2011-09-08 Jinis Biopharmaceuticals Co. Cholesterol lowering supplement and low cholesterol egg produced by using the same
TWI307360B (en) 2004-12-03 2009-03-11 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for constructing strain having compactin hydroxylation ability
WO2006062876A2 (en) 2004-12-09 2006-06-15 Merck & Co., Inc. Estrogen receptor modulators
AU2006302797B2 (en) 2005-03-02 2012-02-02 Merck Canada Inc. Composition for inhibition of cathepsin K
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2008013427A (es) 2006-04-19 2008-11-04 Novartis Ag Compuestos de benzoxazole y benzotiazole sustituidos-6-0 y metodos para inhibir la señalizacion csf-1r.
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
MX2009012679A (es) 2007-05-21 2009-12-11 Novartis Ag Inhibidores de csf-1r, composiciones y metodos de uso.
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
BRPI0821090B8 (pt) 2007-12-21 2021-05-25 Ligand Pharm Inc moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
CN102016054A (zh) * 2008-04-25 2011-04-13 株式会社太平洋 用生物转化系统制备正二羟基异黄酮的方法
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
LT2606134T (lt) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
RU2692799C2 (ru) 2013-10-08 2019-06-27 Мерк Шарп И Доум Корп. Ингибиторы цистеинпротеаз катепсинов
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12552826B2 (en) 2018-08-07 2026-02-17 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3956309A4 (en) 2019-04-19 2023-06-07 Ligand Pharmaceuticals Inc. CRYSTALLINE FORMS AND METHODS FOR PRODUCING CRYSTALLINE FORMS OF A COMPOUND
WO2021126732A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
EP4076459A4 (en) 2019-12-17 2023-12-20 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN120917311A (zh) 2023-03-02 2025-11-07 卡西蒙生物技术有限责任公司 用于诊断癌症和/或急性炎性疾病的手段和方法
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3392171A (en) * 1964-03-20 1968-07-09 Upjohn Co 4-morpholino-4'-hydroxy bicyclohexyls
US3281330A (en) * 1964-03-20 1966-10-25 Upjohn Co Microbiological process for the oxygenation of cycloalkanes
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre

Also Published As

Publication number Publication date
SE8206580L (sv) 1983-05-21
CH651065A5 (de) 1985-08-30
FI823978L (fi) 1983-05-21
JPS5889191A (ja) 1983-05-27
SE8206580D0 (sv) 1982-11-18
DE3242849A1 (de) 1983-06-01
FR2516935A1 (fr) 1983-05-27
KR840002451A (ko) 1984-07-02
ES8402350A1 (es) 1984-01-16
NL194373B (nl) 2001-10-01
BE895080A (fr) 1983-03-16
IT8268359A0 (it) 1982-11-22
DK159328C (da) 1991-02-25
CA1186647A (en) 1985-05-07
DK516182A (da) 1983-05-21
JPH0371116B2 (ref) 1991-11-12
GB2111052B (en) 1985-05-09
ES517542A0 (es) 1984-01-16
SE453996B (sv) 1988-03-21
NL8204505A (nl) 1983-06-16
ZA828535B (en) 1983-10-26
FR2516935B1 (ref) 1985-02-08
FI823978A0 (fi) 1982-11-19
AU9061082A (en) 1983-05-26
US4537859A (en) 1985-08-27
KR880002483B1 (ko) 1988-11-19
GB2111052A (en) 1983-06-29
ATA425182A (de) 1988-07-15
AU551720B2 (en) 1986-05-08
FI70925B (fi) 1986-07-18
AT387585B (de) 1989-02-10
IT1191235B (it) 1988-02-24
NL194373C (nl) 2002-02-04
DE3242849C2 (ref) 1989-01-05
DK159328B (da) 1990-10-01

Similar Documents

Publication Publication Date Title
FI70925C (fi) Foerfarande foer framstaellning av 3-hydroxy-ml-236b-derivaterm-4 och m4'
Iwai et al. Production of deoxyfrenolicin and a new antibiotic, frenolicin B by Streptomyces roseofulvus strain AM-3867
US5153124A (en) Hydroxyl-ml-236b derivatives, their preparation and use
US4421687A (en) Macbecin derivatives
EP1216237B1 (en) Process for the preparation of mycophenolic acid and derivatives thereof
US4421688A (en) Macbecin derivatives
EP0404581A3 (en) Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US4383037A (en) Process to produce anthracycline glycosides
US4199514A (en) Compound, frenolicin B which is useful as an antibiotic
US4375511A (en) Process to produce aclacinomycins A and B
US4540517A (en) Antibiotic TAN-420
GB2106111A (en) Macbecin derivatives and their production
US4981954A (en) Novel azoxy compounds and process for production thereof
US4997755A (en) HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
US5719179A (en) Compound GEX1
US5272174A (en) Hydroxy-ML-236B derivatives, their preparation and use
US4405713A (en) Process for the preparation of optically active anthracycline glycosides A and B
CA2009043A1 (en) Process for the preparation of 6-alpha-hydroxymethyl lovastatin derivatives
EP0337548A3 (en) HMG-COA reductase inhibitors produced by nocardia SP. (MA6455)(ATCC 53695)
Bava et al. Biotransformation of spirolaxine by Absidia cuneospora and Trametes hirsuta: formation of β-glycosyl and β-xylosyl derivatives
US4247703A (en) Microbiological modification of antibiotic A23187 esters
US4287302A (en) Microbiological modification of antibiotic A23187 esters
JPH0538283A (ja) 新規微生物
JPH0365347B2 (ref)
JPH0482135B2 (ref)

Legal Events

Date Code Title Description
MA Patent expired

Owner name: SANKYO COMPANY LIMITED